ClinicalTrials.gg
Status unknownNCT01733940EAC-UCIUpdated Nov 28, 2012

Efficacy of Tegaderm-CHG® Dressing vs. Tegaderm-IV® Dressing

A Phase 4 interventional study of Application of a dressing with clorhexidine gluconate in intravascular catheters. and Application of a dressing without clorhexidine gluconate in Intravascular Catheter Colonization, sponsored by Hospital Central de la Defensa Gómez Ulla. Status unknown at 1 site in Spain. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2012-11-28.

Sponsored by Hospital Central de la Defensa Gómez Ulla · Phase 4, Interventional, and Prevention

How we know

The sponsor has not verified this record recently (last verified Nov 2012), so the status shown — last known as Recruiting — may be out of date.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
398
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

Introduction: The vascular catheter-related bacteremia (BRC) is a major health problem in intensive care units. The use of dressings containing chlorhexidine gluconate (CHG) can decrease the catheters colonization, closely related to infection thereof.

Objective: To determine the efficacy of the dressing "Tegaderm CHG" dressings versus "Tegaderm IV" dressings in reducing the risk of colonization of central intravascular catheters in the intensive care unit (ICU).

Methods: Randomized controlled trial with blinding professional who reviews the main outcome. The study included patients over 18 years, indicating the central intravascular catheter implantation in the ICU or in the operating room, prior informed consent. Excluding subjects with positive blood culture at the time of catheter implantation.

The estimated sample size is 398 patients, with a confidence level of 95% and a statistical power of 80%. The study protocol was approved by the ethics committee of the hospital.

Be made prospectively followed subjects from study entry until catheter removal collecting information on age, sex, APACHEII, antibiotic therapy, duration of catheter insertion site and removal, reason for withdrawal and microbiological information.

For statistical analysis, a model is adjusted multivariate logistic regression, determining the interaction of variables with the likelihood ratio test and confusion by switching between the crude and adjusted effect greater than 10%.

Results and conclusions: The recruitment has started in November 2012 and is scheduled for completion in March 2013. This study will determine whether these new dressings are effective in our environment.

02

Conditions studied

  • Intravascular Catheter Colonization
03

In context

Lead sponsor

Hospital Central de la Defensa Gómez Ulla is the lead sponsor of 4 studies on the registry; 1 is open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria: over 18 years, indicating the central intravascular catheter implantation in the ICU or in the operating room, prior -

Exclusion Criteria:positive blood culture at the time of catheter implantation.

-

Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 4
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Double (Investigator, Outcomes assessor)
Enrollment
398 participants (estimated)

Study arms

  • Experimental
    "Tegaderm CHG" Dressing

    This arm is receiving a clorhexidine dressing for intravascular catheters.

    Device: Application of a dressing with clorhexidine gluconate in intravascular catheters.

  • Active comparator
    "Tegaderm IV" dressing

    Use of tegaderm iv dressings for intravascular catheters. Change each 7 days.

    Device: Application of a dressing without clorhexidine gluconate

Interventions

  • DeviceApplication of a dressing with clorhexidine gluconate in intravascular catheters.
  • DeviceApplication of a dressing without clorhexidine gluconate
06

What researchers measure

Primary outcomes

  1. Incidence of intravascular central catheter colonization.

    Time frame: November 2012- March 2013

Secondary outcomes

  1. Adverse effects of CHG Tegaderm ® dressings.

    Time frame: up to 4 months

07

Study locations

1 of 1 sites recruiting
  • Central Hospital of the Defense
    Madrid, 28047, Spain
    Recruiting
    • ana isabel lopez figueras · Contactalopfi1@oc.mde.es
    • Ana isabel López figueras · Principal investigator
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Sep 2012, a primary completion of Mar 2013 and a completion of Jun 2013. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 21, 2012
First posted
Nov 27, 2012
Start
Sep 2012
Primary completionEst.
Mar 2013
CompletionEst.
Jun 2013
Last update
Nov 28, 2012
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 28, 2012, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01733940
Lead sponsor
Hospital Central de la Defensa Gómez Ulla
Responsible party
ANA ISABEL LÓPEZ FIGUERAS (MD. Facultative of the Preventive Medicine Department, Hospital Central de la Defensa Gómez Ulla) — Principal investigator
First posted
Nov 27, 2012
Start date
Sep 2012
Primary completion
Mar 2013 (estimated)
Completion
Jun 2013 (estimated)
Last update
Nov 28, 2012

Study contacts

ana isabel lopez figueras, MD
Contact
alopfi1@oc.mde.es
0034911586958 ext. 22958

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Nov 2012. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion